Assessing the Real-World Performance of Xylazine Test Strips for Community-Based Drug Checking in Los Angeles

Caitlin A. Molina, BS, BA; Joseph Friedman, MD, PhD, MPH; Adam J. Koncsol, MPA; Ruby Romero, BA; Morgan E. Godvin, BA, Chelsea L. Shover, PhD*

Correspondence to: Chelsea Shover, PhD, CLShover@mednet.ucla.edu

Abstract

Background: The veterinary sedative xylazine is increasingly found in illicit fentanyl and has been associated with numerous health harms. Xylazine test strips (XTS) are an emerging technology that can theoretically assist consumers in avoiding xylazine, but they require real-world validation. We leverage community-based drug checking program data to compare real-world XTS performance to 'gold standard' methods.

Methods: Samples were initially assessed by dissolving 1mg of drug product in 1mL water and dipping an XTS ("first generation" Wisebatch™) in the sample. Subsequently, confirmatory testing was performed by sending samples to the National Institute of Standards and Technology for qualitative analysis using direct analysis in real time mass spectrometry (DART-MS). A subset was analyzed quantitatively with liquid chromatography gas spectrometry (LC/MS) to quantify xylazine, fentanyl, and other compounds.

Results: Of n=595 fentanyl positive samples, n=333 had both DART-MS and XTS data available. N=69 samples were confirmed to contain xylazine by mass spectrometry, of which the majority contained low concentrations (average concentration 2.3%; 78% of samples contained less than <1% xylazine by weight). Of these, n=34 were correctly identified as positive by xylazine test strips, yielding sensitivity of 49.3%. Of n=264 xylazine negative samples, n=235 were correctly categorized (specificity=89.0%).

Conclusions: In our sample, with a large percentage of low-concentration xylazine samples, "first generation" Wisebatch XTS had a relatively low sensitivity, but high specificity. This highlights the value of confirmatory testing and the complicated and often confusing nature of point-of-care test strips for novel substance detection. Follow-up studies are needed.

Keywords: Xylazine Test Strips; Concordance; Validation

Introduction

Xylazine is an alpha-2 adrenergic agonist that causes fast-acting sedation, for which it is used widely as a veterinary sedative[1]. Xylazine is not approved for use in humans. The drug has increasingly been found alongside illicit fentanyl in illicit drug samples and overdose toxicology[2–4]. The addition of xylazine to fentanyl was initially more common in Philadelphia before spreading to other parts of the Eastern US. However, xylazine-adulterated fentanyl has now spread to nearly every state in the US[5], including the West Coast of the US and Northern Mexico[4,6,7].

Xylazine has been associated with numerous health harms for people who use drugs, such as more complicated overdose management[6,8,9] soft tissue infections[10–12], and complex withdrawal syndromes[13]. Furthermore, the subjective experience of xylazine with fentanyl is qualitatively different from that of using opioids alone. For these reasons, many people who use drugs wish to avoid xylazine, but are often unable to do so due to a lack of knowledge of the substance, inability to identify samples that contain it, or a lack of options in the illicit drug market that do not contain it[2,14].

Xylazine test strips (XTS) are an emerging technology that can theoretically assist consumers in avoiding xylazine. They are produced by several manufacturers and are low-cost, usually about $1 USD per strip. They leverage immunoassay technology to offer a presence/absence binary result in less than one minute, describing if xylazine is present in a drug sample[15–17]. Nevertheless, these strips require validation to assess their utility in real-world settings, as evidence regarding their effectiveness has been mixed.

A small pilot study in Rhode Island of n=41 drug samples found xylazine present in n=18 samples according to a 'gold standard' approach leveraging mass spectrometry, however XTS (the 'first generation' of strips produced by BTNX) were only reliably able to detect xylazine in the n=4 samples where it was a 'major component' (>30% by weight) of the drug sample[15]. Despite the small sample size, that study suggested that xylazine test strips may not be able to detect xylazine when it is found at lower concentrations in drug samples[15]. A pilot sample from Tijuana, Mexico, compared two brands of XTS to Direct Analysis in Real Time Mass Spectrometry (DART-MS) [7]. In that sample, n=12 samples tested positive for xylazine on DART-MS confirmatory testing. Of these, Wisebatch XTS correctly identified all n=12, however, also showed n=3 false positives when lidocaine was present. SafeLife XTS had n=0 false positives, but did have n=1 false negative (identifying n=11 total xylazine positive samples). A report from British Columbia found that among n= 152 samples tested using first-generation BTNX XTS and confirmatory testing, sensitivity was 97.7% and specificity was 66.7%. That study also found that a relatively high rate of false positives were likely caused by the presence of ortho-methylfentanyl[18]. The fairly heterogeneous findings noted above highlight that further data are needed to understand the real-world performance of XTS in distinct illicit drug markets.

Here we provide the first West Coast-based study of the real-world performance of XTS on the illicit drug market, leveraging data from a community-based drug checking program in Los Angeles, California. This study draws on n=348 samples with XTS and confirmatory results—the largest sample to date, to our knowledge.

Methods

Drug samples were provided confidentially by anonymous clients using the services of a community-based drug checking program based at several sites in Los Angeles, California. Testing strips for several substances, including xylazine, were employed on-site. XTS were initially used for all samples, and later limited to only those samples bought as or otherwise expected to be fentanyl. Samples were initially assessed by dissolving 1mg of drug product in 1 mL of water and dipping an XTS (from the "first generation" of Wisebatch™ brand strips) in the sample. The strips were read by trained technicians, and a second strip was used in the rare case of an indeterminate result (e.g., faint test line, technician disagreement, etc.).

Confirmatory testing was pursued for the majority of samples, as swabs/vials taken from drug samples were sent to the National Institute of Standards and Technology (NIST) for laboratory-based qualitative testing using DART-MS. A subset also underwent quantitative analysis with liquid-chromatography mass spectrometry (LC-MS).

The confirmatory testing methodologies employed here have been previously described [19,20]. Briefly, the spectra produced by DART-MS analysis were compared against libraries of over 1,300 substances, including pharmaceutical and illicit drugs, adulterants, cutting and bulking agents, precursor chemicals, and other substances (e.g., adhesives, food products, etc.). An LC-MS quantification panel included xylazine, fentanyl, fentanyl precursor chemicals, other illicit drugs, and common adulterants. Substances found to be present, but below the limit of quantification were imputed at 0.01% prevalence.

Data analysis, including descriptive statistics and graphing, were conducted using R 4.1.1. The UCLA Institutional Review Board reviewed and approved this project (protocol IRB-22-0760) and additionally determined that aspects of this work constituted public health surveillance and not human subjects research.

Results

A total of n=1,570 samples were analyzed between June 2023 and May 2025, of which n=536 were fentanyl-positive on DART-MS. A total of n=801 XTS were used, and of these n=715 had confirmatory DART-MS data available for the samples (including n=333 fentanyl-positive samples per DART-MS). A total of N=119 samples were xylazine-positive on DART-MS (20.0% of fentanyl-positive samples). N=87 samples had xylazine quantification data available by mass spectrometry. The majority contained low concentrations. The average xylazine concentration was 2.3% by mass (range: below LOQ [≈0.01%]-56.9%). N=68 (78%) of samples contained less than <1% xylazine by weight.

Among the n=333 XTS testing results available used for the primary analysis, given that they were on fentanyl-positive samples per DART-MS, 100% also had xylazine testing results on DART-MS available. Of these, n=69 samples were confirmed to contain xylazine by mass spectrometry. Among this sample, n=34 were correctly identified as positive by xylazine test strips, yielding sensitivity of 49.3%. Of n=264 xylazine negative samples, n=235 were correctly categorized (specificity=89.0%). Positive predictive value was 54.0% and negative predictive value was 87.0%. Performance statistics on the full sample of n=715 XTS with DART-MS results available were similar (see supplemental table).

False negative results on xylazine test strip qualitatively appeared to be more common among samples with <5% xylazine concentration and were less common with samples above 5% concentration (Figure). However small numbers of samples with higher xylazine concentrations precluded formal hypotheses testing of these differences.

Discussion

This study adds to a small but growing literature describing the real-world performance of XTS, compared to confirmatory testing using mass spectrometry[7,15,18]. With n=333 comparison points in the primary sample (and n=715 comparison points in the supplementary analysis not limited to fentanyl-positive samples), this study represents the largest to-date on this topic to our knowledge, and the first on the West Coast of the U.S. In our sample, with a large percentage of low-concentration xylazine samples, "first generation" Wisebatch xylazine test strips had a relatively low sensitivity, but high specificity. This aligns with a previous smaller study from Rhode Island, which found that XTS may be prone to a high rate of false negative readings among samples that had lower concentrations of xylazine[15]. Our results stand in contrast to another recent report from British Canada, which found a high sensitivity, but low specificity[18]. Nevertheless, the percentage xylazine concentration among samples was not reported in that study, therefore those results may reflect only higher-concentration samples. It is plausible that each study tested different batches/lots of XTS, also affecting XTS performance assessment, as lot-to-lot variability of immunoassay test strip sensitivity has been documented[21]]. In response to early results showing false positives in response to certain cutting agents, such as lidocaine, some XTS manufacturers created a "second generation" of strips designed to reduce such false positives. Further study of subsequent generations of XTS is needed. If additional confirmatory studies continue to show that current generations of XTS are unlikely to detect low concentrations of xylazine, there may be value in the development of XTS with lower detection thresholds. Nevertheless, the clinical relevance of frequent, low-concentration xylazine consumption is also not known, given limited study of xylazine among humans.

This study is limited by the nature of the illicit drug market in Los Angeles, which appears to have an abundance of fentanyl samples with low xylazine concentration. This limited our ability to assess XTS performance at higher concentrations. Given little data nationally on quantitative

testing of xylazine in other drug markets, it remains to be seen how similar the illicit drug market is to other environments, and such differences may affect XTS performance. The study is also only representative of the specific clients who participate in services at Drug Checking Los Angeles sites and may not reflect the entirety of the Los Angeles or West Coast illicit drug market.

The relatively poor performance of XTS in this context highlights the value of laboratory-based testing, especially as subsequent generations of XTS are still in development. The landscape of point-of-care test strips for novel substance detection remains complicated and often confusing for end consumers. Nevertheless, there is clear interest in and demand for rapid technologies that can detect new harmful substances, such as XTS[14]. Follow-up studies on subsequently released test strip products, in more diverse xylazine markets, are needed.

Testing Results				
		Mass Spectrometry		
		Negative	*Positive*	
Testing	*Negative*	235	35	277
Strip	*Positive*	29	34	71
		264	69	333
Summary Statistics				
	Sensitivity	49.28%	PPV	53.97%
	Specificity	89.02%	NPV	87.04%

Table 1. Predictive Performance of Xylazine Testing Strips (Among Fentanyl-Positive Samples)
A comparison is shown between results from xylazine testing strips to confirmatory testing based on DART-MS. Sensitivity, specificity, positive predictive value, and negative predictive value are also calculated. Row and column marginal sums are also shown.

Figure 1. Xylazine Concentration Among False Negatives and True Positives
The distribution of xylazine concentration (by weight) according to LC-MS, among samples with xylazine testing strips results available. Results are shown separate by false negative (shown in red) and true positives (shown in blue).

Declarations

Ethics approval and consent to participate
The UCLA Institutional Review Board reviewed and approved this project (protocol IRB-22-0760) and additionally determined that aspects of this work constituted public health surveillance and not human subjects research.

Availability of data and materials
Data are sensitive and cannot be shared. However, researchers may request summary data from the authors to be provided upon reasonable request.

Competing interests
Authors declare no competing interests.

Funding
JRF received funding from the National Institute on Drug Abuse (DA049644) and the National institute of Mental Health (MH101072). AJK received educational support through the NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI (TL1TR001883). CLS received support from the National Institute on Drug Abuse (K01DA050771 and R01DA057630).

This work was supported by the Centers for Disease Control and Prevention as part of Overdose Data to Action: LOCAL (CDC-RFA-CE-23-0003), and made possible through an equipment grant from the James B. Pendleton Charitable Trust to the UCLA AIDS Institute and UCLA Center for AIDS Research.

Authors' contributions
CLS conceptualized the article, obtained grant funding, and provided overall supervision. All authors participated in the data collection. CAM and JRF wrote the initial draft. CAM and JRF conducted the statistical analysis. CAM, RR, and AJK handled data management. All authors critically reviewed and approved the manuscript.

Acknowledgements
We thank the staff, volunteers, and community partners of Drug Checking Los Angeles for their work to provide services for this client population, and the clients for their engagement in services and efforts to improve them moving forward.

References

1. Gallanosa AG, Spyker DA, Shipe JR, Morris DL. Human Xylazine Overdose: A Comparative Review with Clonidine, Phenothiazines, and Tricyclic Antidepressants. Clinical Toxicology. 1981;18:663–78.

2. Friedman J, Castillo FM, Bourgois P, Wahbi R, Dye D, Goodman D, et al. Xylazine Spreads Across the US: A Growing Component of the Increasingly Synthetic and Polysubstance Overdose Crisis [Internet]. 2021 Sep p. 2021.09.20.21263680. Available from: https://www.medrxiv.org/content/10.1101/2021.09.20.21263680v1

3. Cano M, Daniulaityte R, Marsiglia F. Xylazine in Overdose Deaths and Forensic Drug Reports in US States, 2019-2022. JAMA Network Open. 2024;7:e2350630.

4. Friedman J, Molina CA, Koncsol AJ, Romero R, Godvin ME, Jalayer E, et al. Xylazine Prevalence and Concentration in the Los Angeles Fentanyl Market, 2023 Q1 – 2025 Q2 [Internet]. medRxiv; 2025 [cited 2025 Jun 5]. p. 2025.05.13.25327478. Available from: https://www.medrxiv.org/content/10.1101/2025.05.13.25327478v1

5. Friedman JR. Assessing an ICD-10 Code Approach for Tracking Xylazine-Involved Overdose Deaths in the United States [Internet]. medRxiv; 2024 [cited 2025 Feb 5]. p. 2024.11.27.24318111. Available from: https://www.medrxiv.org/content/10.1101/2024.11.27.24318111v1

6. Bufanda LP, Montoya AG, Carrillo BT, Tejeda MAG, Segovia LA, Calderón-Villarreal A, et al. Managing xylazine-involved overdoses in a community harm reduction setting: lessons from Tijuana, Mexico. Harm Reduct J. 2025;22:2.

7. Friedman JR, González Montoya A, Ruiz C, González Tejeda MA, Segovia LA, Godvin ME, et al. The Detection of Xylazine in Tijuana, Mexico: Triangulating Drug Checking and Clinical Urine Testing Data. Journal of Addiction Medicine. 2024;10.1097/ADM.0000000000001474.

8. German D, Genberg B, Sugarman O, Saloner B, Sawyer A, Glick JL, et al. Reported xylazine exposure highly associated with overdose outcomes in a rapid community assessment among people who inject drugs in Baltimore. Harm Reduct J. 2024;21:18.

9. Zhu DT. Public health impact and harm reduction implications of xylazine-involved overdoses: a narrative review. Harm Reduct J. 2023;20:131.

10. McFadden R, Wallace-Keeshen S, Petrillo Straub K, Hosey RA, Neuschatz R, McNulty K, et al. Xylazine-associated Wounds: Clinical Experience From a Low-barrier Wound Care Clinic in Philadelphia. Journal of Addiction Medicine. 2024;18:9.

11. Jawa R, Ismail S, Shang M, Murray S, Murray-Krezan C, Zheng Y, et al. Drug use practices and wound care experiences in the age of xylazine adulteration. Drug Alcohol Depend. 2024;263:112390.

12. Dowton A, Doernberg M, Heiman E, Barelli P, Golden M, Wang H, et al. Recognition and Treatment of Wounds in Persons Using Xylazine: A Case Report From New Haven, Connecticut. J Addict Med. 2023;17:739–41.

13. Ehrman-Dupre R, Kaigh C, Salzman M, Haroz R, Peterson L-K, Schmidt R. Management of Xylazine Withdrawal in a Hospitalized Patient: A Case Report. Journal of Addiction Medicine. 2022;16:595.

14. Reed MK, Imperato NS, Bowles JM, Salcedo VJ, Guth A, Rising KL. Perspectives of people in Philadelphia who use fentanyl/heroin adulterated with the animal tranquilizer xylazine; Making a case for xylazine test strips. Drug and Alcohol Dependence Reports. 2022;4:100074.

15. Thompson E, Tardif J, Ujeneza M, Badea A, Green TC, McKee H, et al. Pilot findings on the real-world performance of xylazine test strips for drug residue testing and the importance of secondary testing methods. Drug Alcohol Depend Rep. 2024;11:100241.

16. Evaluation of Xylazine Test Strips (BTNX) for Drug Checking Purposes [Internet]. CFSRE; 2023. Available from: https://www.cfsre.org/nps-discovery/drug-checking/evaluation-of-xylazine-test-strips-btnx-for-drug-checking-purposes

17. Sisco E, Appley MG, Pyfrom EM, Banta-Green CJ, Shover CL, Molina CA, et al. Beyond Fentanyl Test Strips: Investigating Other Urine Drug Test Strips for Drug Checking Applications [Internet]. 2024 [cited 2024 Apr 16]. Available from: https://chemrxiv.org/engage/chemrxiv/article-details/660720459138d23161b43dfd

18. Angelluci J, Mathews J, Ruiz Orduna A. Detection of xylazine by immunoassay test strips in community drug samples: Phase 2 report. The British Columbia Centre on Substance Use;

19. Sisco E, Verkouteren J, Staymates J, Lawrence J. Rapid detection of fentanyl, fentanyl analogues, and opioids for on-site or laboratory based drug seizure screening using thermal desorption DART-MS and ion mobility spectrometry. Forensic Chemistry. 2017;4:108–15.

20. Appley MG, Robinson EL, Thomson A, Russell E, Sisco E. An Analytical Platform for Near Real-Time Drug Landscape Monitoring using Paraphernalia Residues [Internet]. 2022 [cited 2024 Aug 29]. Available from: https://chemrxiv.org/engage/chemrxiv/article-details/6399d42e04bc66316815f362

21. Halifax JC, Lim L, Ciccarone D, Lynch KL. Testing the test strips: laboratory performance of fentanyl test strips. Harm Reduct J. 2024;21:14.

Testing Results				
		Mass Spectrometry		
		Negative	*Positive*	
Testing	*Negative*	614	36	650
Strip	*Positive*	31	34	65
		645	70	715
Summary Statistics				
	Sensitivity	48.57%	PPV	52.31%
	Specificity	95.19%	NPV	94.46%

Supplemental Table 1. Predictive Performance of Xylazine Testing Strips Among Full Sample, Not limited to Fentanyl Positive Samples
A comparison is shown between results from xylazine testing strips to confirmatory testing based on DART-MS. Sensitivity, specificity, positive predictive value, and negative predictive value are also calculated. Row and column marginal sums are also shown.